1
Clinical Trials associated with CART-138(Chinese PLA General Hospital) / Unknown statusPhase 1/2IIT Clinical Study of Chimeric CD(Cluster of Differentiation)138 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Multiple Myelomas
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
PURPOSE: This clinical trial is to study genetically engineered lymphocyte therapy in treating patients with CD138 positive multiple myeloma that is relapsed (after stem cell transplantation or intensive chemotherapy) or refractory to further chemotherapy.
100 Clinical Results associated with CART-138(Chinese PLA General Hospital)
100 Translational Medicine associated with CART-138(Chinese PLA General Hospital)
100 Patents (Medical) associated with CART-138(Chinese PLA General Hospital)
100 Deals associated with CART-138(Chinese PLA General Hospital)